Antibodies against AXL, pIGF-1R (Y1135/6), IGF-1R, pSrc (Y416), Src, pMet (Y1234/5), Met, tubulin, and cleaved caspase-3 were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against cleaved PARP were purchased from BD Biosciences (San Jose, CA, USA). Antibodies against pAXL (Y702) were purchased from R&D systems (Minneapolis, MN, USA). Primary antibodies against IGF-1R and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies against pIR/IGF-1R (Y1162/3) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Horseradish peroxidase-conjugated secondary antibodies were purchased from GeneTex (Irvine, CA, USA). Linsitinib, dasatinib, and bemcentinib (R428) were purchased from Selleckchem (Houston, TX, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. The detailed information on used primary and secondary antibodies, including vendor, catalogue number, application, and dilution ratio (or concentration) is listed in Table S1.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.